Australasian Myeloma Research Consortium

With PBS reimbursement from 1 June 2020 of the bortezomib, lenalidomide and dexamethasone (VRD) triplet as frontline treatment for newly diagnosed myeloma, the Australian Amyloidosis Network would like to highlight the reported international experience of VRD in systemic AL amyloidosis, and provide a note of caution.

Calling all researchers whose trial has been affected by COVID-19, pls consider spending 10mins to complete this GLOBAL SURVEY https://wellcome.ac.uk/what-we-do/our-work/good-clinical-trials-collaborative to capture overall impact & innovate future research practice #clinicaltrials

Given the abundance of research supporting that sexual concerns are highly prevalent in cancer survivors, it follows that this could also be true for patients with multiple myeloma specifically. The study is run by University of Calgary and Tom Baker Cancer Centre in Canada.